News for Biomea Fusion, Inc. (BMEA)

Biomea Fusion (BMEA) has announced a strategic addition to its Board of Directors with the appointment of Julianne Averill, starting on July 22, 2025. Along wit

Julianne Averill appointed to Biomea Fusion's Board of Directors, effective July 22, 2025. Averill brings over 20 years of experience in life sciences a

SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (”œBiomea,” ”œBiomea Fusion” or the ”œCompany”) ( BMEA), a clinical-stage d

Biomea Fusion (BMEA) received a reaffirmation of its "Buy" rating from analyst Jason Kolbert at D. Boral Capital. The analyst maintained a consistent price targ

On July 16, 2025, Citigroup analyst Yigal Nochomovitz announced an update regarding Biomea Fusion (BMEA), maintaining a 'Buy' rating on the stock. Despite this,

Biomea Fusion (BMEA) recently had its price target cut by Citi from $22 to $9, although the firm maintains a Buy rating on the stock. This adjustment comes as t

H.C. Wainwright analyst Joseph Pantginis has adjusted the price target for Biomea Fusion (BMEA), reducing it from $18 to $4, while maintaining a Buy rating on t

Biomea Fusion (BMEA) recently unveiled new preclinical and clinical data on their investigational oral menin inhibitor, icovamenib, at the 85th Scientific Sessi

Biomea Fusion's icovamenib shows promising results in type 2 diabetes treatment with 1.0% placebo-adjusted HbA1c reduction. The drug, when combined with

Market Overview The stock market appeared stable with major indices showing little change, yet underlying geopolitical and Federal Reserve factors added comp

U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining around 0.2% on Wednesday. The Dow traded up 0.26% to 42,324.65 while the NASDAQ r...

Stock News● Safran (SAFRF, SAFRY) must divest certain assets to proceed with its $1.8 billion acquisition of RTX Corp.'s (RTX) Collins Aerospace division, as

Biomea Fusion (BMEA) has shared encouraging preclinical results from a weight loss investigation involving the experimental drug BMF-650. This trial, which span

BMF-650 achieved 12-15% weight reduction in preclinical trials with obese cynomolgus monkeys. Significant reduction in food intake observed, indicating

Shares of Beyond Air, Inc. XAIR fell sharply in today's pre-market trading after the company posted mixed fourth-quarter results. Beyond Air reported quarterly...

BioMarin Pharmaceutical Inc. (BMEA) has announced a new stock offering, which has been priced lower than its previous closing price of $2.90. Jefferies is takin

**media[582026]**

**media[576596]**

This week's earnings include retailers like Dick’s Sporting Goods, Dollar General, and Kohl’s. Investors will look for Feb. CPI reading that is due Wednesday. See more.